Skip to content

Non-invasive neuromodulation in the treatment of pain and sensory abnormalities in parkinson's disease and exploration in the mechanism

Non-invasive neuromodulation in the treatment of pain and sensory abnormalities in parkinson's disease and exploration in the mechanism

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300072032
Enrollment
Unknown
Registered
2023-05-31
Start date
2023-06-15
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

Experimental group:trancranial direct current stimulation
Experimental group:transcranial magnetic stimulation
Control group:sham trancranial direct current stimulation
Health control:Motor cortical excitability is measured by transcranial magnetic stimulation

Sponsors

First Affiliated Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1.Parkinson's disease meet the recent diagnostic criteria developed by Movement Disorder Society;2.The KPPS score is higher than or equal to 1 point or VAS score of sensory abnormalities is higher than 0 point,and the duration of PD-related pain or sensory abnormalities symptoms is greater than or equal to 1 month;3. Subjects who can complete transcranial magnetic stimulation and transcranial direct current stimulation.

Exclusion criteria

Exclusion criteria: 1. There are cerebral hemorrhage, cerebral infarction, poisoning, trauma and other lesions that can clearly lead to movement disorders; 2. Patients with scalp trauma, infection, tumor, etc. who are not suitable for wearing the instrument; 3. Patients with intracranial hypertension, epilepsy and other contraindications to transcranial magnetic stimulation and transcranial direct current stimulation; 4. Individuals who are old, weak, or unable to cooperate in completing experimental operations; Clear lesions such as cerebral hemorrhage, cerebral infarction, poisoning, and trauma that can lead to Parkinson's symptoms; 5. The results of the Mini-mental State Examination (MMSE) indicate patients with cognitive impairment.

Design outcomes

Primary

MeasureTime frame
short latency afferent inhibition;long latency afferent inhibition;resting motor threshold;ipsilateral silent period;KING's Parkinson's Disease Pain Scale;visual analogue scale;Movement Disorder Society Unified-Parkinson Disease Rating Scale;

Secondary

MeasureTime frame
Mini-mental state examination;HAMD-17;HAMA;SCOPA-AUT;Non-Motor Symptoms Scale ;The Epworth Sleeping Scale;REM sleep behavior disorder questionnaire—Hong Kong;The Parkinson's Disease Questionnaire;tactile threshold;pain threshold;pain tolerance;finger tapping test ;foot tapping test;integral electromyoelectric value ;root mean square value of electromyoelectric;Parkinson’s Disease Fatigue Scale ;Parkinson’s Disease Fatigue Scale -2;Hoehn and Yahr scale;

Countries

China

Contacts

Public ContactXianwen Chen

The First Affiliated Hospital of Anhui Medical University

chxwmail@aliyun.com+86 139 5693 9016

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026